Health Enhancement Products, Inc. Expands Intellectual Property Development Effort With Preeminent Research Scientist and Patent CounselPosted On: April 13, 2012
Arizona-based algae producer Health Enhancement Products (OTCBB: HEPI) has engaged preeminent research scientist Dr. William Gerwick, Distinguished Professor of Oceanography and Pharmaceutical Sciences at the Center for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography and the Skaggs School of Pharmacy and Pharmaceutical Sciences located in the La Jolla campus of the University of California at San Diego.
Dr. Gerwick’s current research focuses on the discovery of bioactive molecules with potential anticancer, antibacterial, neurotoxic, antiviral, or anti-inflammatory activity from marine organisms, such as algae. The pathways by which these complex molecules are assembled form the basis of Dr. Gerwick’s research, using stable isotope tracer methods and NMR analysis. Many marine algae produce prostaglandin and leukotriene analogs that are strikingly similar to substances produced in the human body, and that have therapeutic value as potential pharmacological agents.
Health Enhancement Products, Inc. expands scientific inquiry at Battelle as algae-derived molecules are tested for bioactivityPosted On: November 27, 2011
The board directors of Health Enhancement Products, Inc. (OTCBB: HEPI), a Scottsdale, AZ-based food ingredients and nutraceutical enterprise, has authorized an expanded study of its algae extracts. Since May of 2011, the Company has been working with Battelle, the world’s largest independent research and development organization, to isolate the active molecules in its proprietary algae extract, specifically those natural compounds responsible for supporting a healthy cholesterol balance. Over the intervening months, Battelle research scientists have conducted a series of experiments to separate bioactive fractions of the algae extract in order to isolate and further characterize the bioactive components.
That program has resulted in a number of isolates that can now be tested in vivo. The in vivo portion of this expanded research project will be carried out in several steps. The in vivo study is expected to commence in several days. The isolated samples will be administered to test subjects over the course of 30 days, after which an evaluation process would identify those samples with bioactivity. Battelle scientists would subject those samples to further refinement and validation, or proceed directly to a final analysis.